A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies Naval G. Daver 1 , Harry P. Erba 2 , Nikolaos Papadantonakis 2 , Daniel J. DeAngelo 3 , Eunice S. Wang 4 , Marina Konopleva 1 , Callum M. Sloss 5 , Kerry Culm-Merdek 5 , Patrick A. Zweidler- McKay 5 , and Hagop M. Kantarjian 1 1 MD Anderson Cancer Center, Houston, TX; 2 University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; 3 Dana- Farber Cancer Inst., Boston, MA; 4 Roswell Park Comprehensive Cancer Center, Buffalo, NY; 5 ImmunoGen, Inc., Waltham, MA IMGN632 in R/R AML and BPDCN, abstract #27
16
Embed
A Phase I, First-in-Human Study Evaluating the Safety and … · 2018. 12. 3. · – reversible veno-occlusive disease (VOD) (2 DLTs) • 0.45 mg/kg moderate VOD, alloSCT for MDS
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
A Phase I, First-in-Human Study Evaluating the Safety
and Preliminary Antileukemia Activity of IMGN632, a
Novel CD123-Targeting Antibody-Drug Conjugate, in
Patients with Relapsed/Refractory Acute Myeloid
Leukemia and Other CD123-Positive Hematologic
Malignancies
Naval G. Daver1, Harry P. Erba2, Nikolaos Papadantonakis2,
Daniel J. DeAngelo3, Eunice S. Wang4, Marina Konopleva1,
Callum M. Sloss5, Kerry Culm-Merdek5, Patrick A. Zweidler-
McKay5, and Hagop M. Kantarjian1
1MD Anderson Cancer Center, Houston, TX; 2University of Alabama at
Birmingham Comprehensive Cancer Center, Birmingham, AL; 3Dana-
Farber Cancer Inst., Boston, MA; 4Roswell Park Comprehensive Cancer
Center, Buffalo, NY; 5ImmunoGen, Inc., Waltham, MA
IMGN632 in R/R AML and BPDCN, abstract #27
CD123 as a Therapeutic Target
• CD123, the a-subunit of interleukin-3 receptor (IL-3Ra), is
expressed in the majority of AML and nearly all BPCDN (blastic
plasmacytoid dendritic cell neoplasm) and B-cell acute
lymphoblastic leukemia (B-ALL) cases1,2
• CD123 is elevated on AML blasts and leukemic stem cells
compared with normal hematopoietic stem and progenitor cells3
• CD123-directed therapy may be able to de-bulk and potentially
eliminate the source of disease
• CD123 is rapidly internalized making it well suited for antibody-
drug conjugate (ADC)-based therapeutic strategies
1Testa 2014 Biomarker Res 2:4; 2Khoury 2018 Haematologica; 3Ehninger 2014 Blood Cancer J 4:e218;